News CARGO offloads staff after abandoning lead CAR-T Less than 18 months after its IPO, CAR-T developer CARGO has abandoned its development efforts and slashed around 90% of its staff.
News BMS absorbs CAR-T partner 2seventy bio for $286m Bristol Myers Squibb has moved to take full control of the CAR-T therapy it partners with 2seventy bio, agreeing to buy the biotech for around $286m.
News NICE changes its mind on BMS' lymphoma cell therapy Around 600 people with various types of B-cell lymphoma will be eligible for treatment with BMS' CAR-T therapy Breyanzi under new NICE guidance.
News CARsgen gets a win for CAR-T in solid tumours CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satri-cel has shown efficacy in gastric cancer, setting up a filing in China.
Oncology Transforming autoimmune disease therapy: Post-ACR 2024 persp... The 2024 American College of Rheumatology (ACR) annual meeting spotlighted transformative advancements in cell therapies for autoimmune diseases, with chimeric antigen receptor (CAR)-T ther
Oncology Can CAR-T first movers keep pace in a rapidly evolving marke... The CAR-T landscape has quickly transformed from a pioneering breakthrough to a highly competitive and evolving market.
News Japan follows UK in GSK's comeback tour for Blenrep The revitalisation of GSK's blood cancer therapy Blenrep continues with a second approval, in Japan, as a second-line treatment for multiple myeloma.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.